BOUCHERVILLE, QC, Sept. 26,
2024 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL)
("LSL Pharma" or the "Corporation"), an integrated
Canadian-based pharmaceutical Corporation, today announced a change
of auditor from KPMG LLP (the "Predecessor Auditor") to
Audacie Inc. (the "Successor Auditor").
The Predecessor Auditor has resigned as auditor of the
Corporation effective September 25,
2024 at the request of the Corporation to facilitate the
appointment of Audacie as successor auditor of the Corporation. The
Board of Directors of the Corporation, on the recommendation of the
Corporation's Audit Committee, approved the appointment of the
Successor Auditor to replace the Predecessor Auditor, effective
September 25, 2024.
There were no modified opinions in the Predecessor Auditor's
audit reports relating to the fiscal years ended December 31, 2023 and 2022 or any subsequent
period until its resignation date and there is no "reportable
event" as such term is defined in Part 4.11 of National Instrument
51-102- Continuous Disclosure Obligations ("NI 51-102").
The Corporation has filed the change of auditor reporting
package on SEDAR+ in accordance with NI 51-102.
GRANT OF OPTIONS
The Corporation also announces the grant of an aggregate of
465,270 stock options (the "Options") to certain officers and
directors in accordance with the Corporation's long-term incentive
compensation plan. The Options will be exercisable at a price of
$0.45 per Class A common share, will
vest over three years and have a ten-year term.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements as
defined under applicable Canadian securities legislation.
Forward-looking statements can generally be identified by the use
of forward-looking terminology such as "may", "will", "expect",
"intend", "estimate", "continue" or similar expressions.
Forward-looking statements are based on a number of assumptions and
are subject to various known and unknown risks and uncertainties,
many of which are beyond the Corporation's ability to control or
predict, that could cause actual results or performance to differ
materially from those expressed or implied in such forward-looking
statements. These risks and uncertainties include, but are not
limited to, those identified in the Corporation's filings with
Canadian securities regulatory authorities, such as legislative or
regulatory developments, increased competition, technological
change and general economic conditions. All forward-looking
statements made herein should be read in conjunction with such
documents.
Readers are cautioned not to place undue reliance on
forward-looking statements. No assurance can be given that any of
the events referred to in the forward-looking statements will
transpire, and if any of them do, the actual results, performance
or achievements of the Corporation may differ materially from those
expressed or implied by the forward-looking statements. All
forward-looking statements contained in this press release speak
only as of the date of this press release. The Corporation does not
undertake to update these forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
ABOUT LSL PHARMA GROUP INC.
LSL Pharma Group Inc. is an integrated Canadian-based
pharmaceutical company specializing in the development,
manufacturing, and commercialization of high-quality sterile
ophthalmic pharmaceuticals, as well as natural health products
in solid and liquid dosage forms. For further information, please
visit our website www.groupelslpharma.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE Groupe LSL PHARMA INC.
